These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31262041)

  • 21. Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma.
    Chiang PJ; Xu T; Cha TL; Tsai YT; Liu SY; Wu ST; Meng E; Tsao CW; Kao CC; Chen CL; Sun GH; Yu DS; Chang SY; Yang MH
    Biology (Basel); 2021 Jul; 10(7):. PubMed ID: 34356529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
    Yoneda K; Imanishi N; Ichiki Y; Tanaka F
    J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer.
    Kallergi G; Vetsika EK; Aggouraki D; Lagoudaki E; Koutsopoulos A; Koinis F; Katsarlinos P; Trypaki M; Messaritakis I; Stournaras C; Georgoulias V; Kotsakis A
    Ther Adv Med Oncol; 2018; 10():1758834017750121. PubMed ID: 29383038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
    Ikeda M; Koh Y; Teraoka S; Sato K; Oyanagi J; Hayata A; Tokudome N; Akamatsu H; Ozawa Y; Endo K; Higuchi M; Nakanishi M; Ueda H; Yamamoto N
    Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34064720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inter- and intraobserver agreement of the quantitative assessment of [
    Hughes DJ; Chand G; Goh V; Cook GJR
    EJNMMI Res; 2020 Dec; 10(1):145. PubMed ID: 33259032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
    Althammer S; Tan TH; Spitzmüller A; Rognoni L; Wiestler T; Herz T; Widmaier M; Rebelatto MC; Kaplon H; Damotte D; Alifano M; Hammond SA; Dieu-Nosjean MC; Ranade K; Schmidt G; Higgs BW; Steele KE
    J Immunother Cancer; 2019 May; 7(1):121. PubMed ID: 31060602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
    Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
    Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients.
    Katsarou SD; Messaritakis I; Voumvouraki A; Kakavogiannis S; Κotsakis A; Alkahtani S; Stournaras C; Martin SS; Georgoulias V; Kallergi G
    J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer.
    Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q
    PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy.
    Yue C; Jiang Y; Li P; Wang Y; Xue J; Li N; Li D; Wang R; Dang Y; Hu Z; Yang Y; Xu J
    Oncoimmunology; 2018; 7(7):e1438111. PubMed ID: 29900038
    [No Abstract]   [Full Text] [Related]  

  • 35. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.
    Strati A; Economopoulou P; Lianidou E; Psyrri A
    Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer.
    Remon J; Chaput N; Planchard D
    Curr Opin Oncol; 2016 Mar; 28(2):122-9. PubMed ID: 26756384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer.
    Shen X; Zhao Y; Liu G; Zhou HL; Fan J; Zhang L; Li YL; Wang Y; Liang J; Xu ZX
    Life Sci; 2020 Sep; 256():117923. PubMed ID: 32522567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer.
    Wang Y; Kim TH; Fouladdel S; Zhang Z; Soni P; Qin A; Zhao L; Azizi E; Lawrence TS; Ramnath N; Cuneo KC; Nagrath S
    Sci Rep; 2019 Jan; 9(1):566. PubMed ID: 30679441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.